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 Abstract - Blastic plasmacytoid dendritic cell 
neoplasm (BPDCN), an extremely rare and 
aggressive tumor, derives from plasmacytoid 
dendritic cell precursors and is characterized by CD4 
and CD56 positivity accompanied by the expression 
of isolated myeloid, B- or T-cell lineage markers. 
Despite the recent introduction of specific targeted 
therapies, prognosis is still poor with a median 
overall survival of one year, and allogeneic bone 
marrow transplantation remains the only curative 
treatment in eligible patients. In this series, we 
described two cases of adult BPDCN treated with 
high dose cytarabine and methotrexate and 
autologous hematopoietic stem cell transplantation, 
or fludarabine, cytarabine, and idarubicin achieving 
the first a complete lasting remission, while the 
second only a transient improvement in skin lesions.  
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I.  INTRODUCTION 
 
 Blastic plasmacytoid dendritic cell neoplasm 
(BPDCN), a rare and aggressive hematological disease, 
has been recognized as a distinct clinical entity in 2016 
revision of the World Health Organization (WHO) 
classification of myeloid neoplasms and acute leukemia 
[1]. BPDCN mostly affects older males (mean age, 70 
years) and is characterized by skin lesions with or without 
bone marrow (BM) involvement and leukemic cell 
dissemination in secondary lymphoid organs [1-6]. In 
addition, 10-20% of patients have a clinical history of 
other hematological malignancies, such as 
myelodysplastic syndrome (MDS) or chronic myeloid 
leukemia [1]. BPDCN cells are of plasmacytoid dendritic 
cell origins and typically express CD4, CD123 
(interleukin-3 a receptor), HLA-DR, cTCL1 (cytoplasmic 
T-cell leukemia/lymphoma 1) at high levels, CD56, 
CD304, CD303, CD36, CD38, and CD45RA [7-8]. 
Chromosomal abnormalities, such as complex karyotype 
with deletions on chromosomes 5q21 or 5q34, and 
somatic mutations in genes like CDKN1B/2A, TET2 or 
TP53 are also frequently reported [7-11]. To date, there 
are no guidelines for treatment of advanced BPDCN; 
however, conventional chemotherapy used for myeloid or 
lymphoid malignancies are employed with various 
efficacy [12-13]. Recently, a cytotoxin targeting CD123-
expressing cells, tagraxofusp-erzs, has been approved for 
BPDCN with an overall response rate [ORR] of 90% as 
frontline therapy or 67% in relapsed/refractory patients 
[14-15]. However, available studies show that overall 
survival (OS) is similar between patients receiving 
conventional chemotherapy and those treated with 
tagraxofusp-erzs [4]. High dose cytarabine and 
methotrexate (CVAD) and hematopoietic stem cell 
transplantation (HSCT) remain the most effective 
therapies for BPDCN treatment in eligible subjects [4]. 
With the advances in diagnosis and the appliance of novel 
targeted regimen, the outcomes for patients with BPDCN 
may be improved in the future. 
 In this series, we presented two cases of BPDCN 
treated at the Hematology and Transplant Center, 
University Hospital “San Giovanni di Dio e Ruggi 
d’Aragona” of Salerno after informed consent obtained in 
accordance with the Declaration of Helsinki [16]. The 
authors retrospectively reviewed all available medical 
records.  
 
II.  CASE 1 PRESENTATION 
 
Skin biopsy and immunophenotyping were 
performed in a 48-year-old female presented with 
progressive erythematous lesions of lower limbs not 
improving after a two-year treatment with steroids and 
colchicine, and a medical history of vitiligo and pityriasis 
versicolor. She received a diagnosis of BPDCN in April 
2014, and leukemic cells were positive for CD4, CD2, 
CD38, CD56, CD123, and Ki67. No extracutaneous or 
BM involvements were found after PET-CT scanning and 
marrow biopsy. She started chemotherapy according to 
the hyper-CVAD scheme: cycle A with 
cyclophosphamide, doxorubicin, and vincristine; and four 
cycles B with methotrexate and subcutaneous cytarabine 
(Ara-C). Skin lesions gradually disappeared right after 
chemotherapy, and she was candidate to autologous 
HSCT. Peripheral blood stem cells (PBSCs) were 
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collected at the end of the third cycle B, and conditioning 
regimen with busulfan 2 mg/m
2
 and melphalan 130 mg/m
2
 
was started after seven months from diagnosis. Post-
transplant complications were persistent diarrhea, herpes 
zoster reactivation, severe peripheral neuropathy, and 
recurrent bronchitis, all successfully treated. At the time 
of writing, after six years from HSCT, the patient is alive 
without signs and symptoms of BPDCN. 
 
III.  CASE 2 PRESENTATION 
 
A 55-year-old man received a diagnosis of 
refractory anemia based on 2016 World Health 
Organization criteria with an International Prognostic 
Scoring System (IPSS) of 0 in January 2017 [1]. 
Peripheral blood and BM flow cytometry 
immunophenotype showed the presence of aberrant 
CD14+CD33+CD56+ monocytes. The patient was treated 
with supportive therapy (epoetin alfa 40.000 IU/weekly) 
until April 2020 when rapid progressive erythematous 
skin lesions appeared. Skin biopsy highlighted an 
infiltration of CD56+CD4+CD3+/- pathological cells with 
focal expression of MUM1 posing for a diagnosis of 
BPDCN. No extracutaneous involvements were found 
after PET-CT scanning, while BM biopsy confirmed the 
diagnosis of MDS with trisomy 8. Because of low Eastern 
Cooperative Oncology Group Performance Status (ECOG 
PS = 1), the patient started a reduced intensity FLAG-IDA 
protocol (fludarabine, Ara-C, and idarubicin), and skin 
lesions immediately reduced in number and size (Figure 
1). However, blood counts and clinical conditions rapidly 
worsened after one month, and he died because of disease 
progression with neurological and hepatic involvement 
and severe pancytopenia. 
 
 
Fig. 1. Clinical presentation of Case 2. 
(A) The patient presented with erythematous infiltrated skin lesions all 
over the body that were disappearing (B) just after ten days of treatment. 
 
 
 
 
IV.  DISCUSSION 
 
 BPDCN is a rare disease that behaves like high-
risk acute leukemia with poor prognosis because no 
specific therapies or consensus on frontline treatment are 
present, and because BPDCN frequently shows 
chemoresistance. In young patients, intensive induction 
regimens followed by consolidation and HSCT are 
considered the most effective treatment strategy, leading 
to lasting responses, while treatment of elderly patients is 
still challenging. 
In our experience, we presented two adult 
BPDCN cases treated with hyper-CVAD and autologous 
HSCT or a FLAG-IDA protocol. The first patient who 
quickly received HSCT achieved a long-lasting complete 
remission; however, she had several transplant-related 
complications. The second case was treated with a 
reduced intensity FLAG-IDA because of low non-optimal 
performance status and progression of previously 
diagnosed MDS. This patient experienced a rapid but 
transient improvement in skin lesion; however, he died 
after one month because of disease progression. 
Therefore, our results confirmed that hyper-CVAD 
treatment followed by HSCT could be the most effective 
therapeutic strategy for long-lasting remission in BPDCN 
patients as previously reported [4]. In particular, 
allogeneic HSCT recipients have a 10-year OS of 40% 
with better outcomes when transplant is performed at the 
first remission [17-18]. In non-eligible patients, 
autologous HSCT can be an effective alternative, as 
shown in our case report. Tagraxofusp, bortezomib, 
azacytidine or venetoclax could also be a valid therapeutic 
option as preliminary results show significant 
improvements in ORR [14,19-24]. However, further 
studies are required to define the best strategy for 
treatment of BPDCN and to identify candidate biomarkers 
of responsiveness to therapies.  
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